Peptide research profile

Tirzepatide

Also known as GIP/GLP-1 dual agonist · Mounjaro · Zepbound

A once-weekly dual GIP and GLP-1 receptor agonist with large phase 3 programs and regulated indications for type 2 diabetes and chronic weight management.

  • Metabolic research
Established human evidence2 referencesEducational use

Dosing literacy

Dosing & scaling, explained

Tirzepatide uses a regulator-defined escalation ladder. The calculator preset mirrors the 2.5 mg initiation amount, not the maintenance doses tested for long-term outcomes. This is educational source context—not a protocol or recommendation.

Scaling framework

How sourced amounts are organized

  1. Initiation2.5 mg / week
    First 4 weeks

    Used to start treatment and improve tolerability.

  2. Early maintenance5 mg / week
    After initiation

    The first maintenance level; further increases are based on response and tolerability.

  3. Higher trial doses10–15 mg / week
    After stepwise escalation

    SURMOUNT-1 tested 5, 10, and 15 mg maintenance arms.

Do not translate an approved pen dose into research-vial units without verifying concentration and formulation.

Schedule literacy

Patterns described in source material

  • Once weekly

    The clinical formulation is designed for weekly use.

  • 2.5 mg increments

    Escalation generally occurs no more frequently than every four weeks.

  • Product-specific

    Follow current labeling for missed doses, interruptions, and contraindications.

Clinical context
  • 5, 10, or 15 mg · Once weeklySURMOUNT-1 maintenance arms20-week escalation period

Weekly doses from 5 to 15 mg have extensive phase 3 data after gradual escalation.

Research best practices

Storage, handling and interpretation

Lyophilized material

Keep cold, dry, and protected from light according to the manufacturer certificate or validated lab SOP.

After reconstitution

Use sterile technique, refrigerate as validated, and avoid repeated freeze–thaw cycles.

Traceability

Record lot, concentration, preparation date, and the identity/purity documentation used by the lab.

Research orientation

What researchers are exploring

These themes describe recurring questions in published research. They are not claims of effectiveness or recommendations for use.

  • 01

    Weight management

    SURMOUNT trials evaluate weekly 5, 10, and 15 mg maintenance doses after escalation.

  • 02

    Type 2 diabetes

    SURPASS trials examine glycaemic outcomes across a range of comparators.

  • 03

    Diabetes prevention

    Longer follow-up evaluates progression from prediabetes in participants with obesity.

  • 04

    Tolerability

    Gastrointestinal events cluster during dose escalation and are dose-dependent.

Evidence map

What the current evidence can support

Study models remain visible so laboratory and animal findings are not mistaken for established human outcomes.

  • Human

    SURMOUNT-1 phase 3 trial

    A 72-week randomized trial compared weekly 5, 10, and 15 mg doses with placebo in 2,539 adults without diabetes.

  • Human

    Three-year follow-up

    A prespecified population with obesity and prediabetes was followed through 176 weeks of treatment.

  • Review

    Regulated dose ladder

    The 2.5 mg initiation step is followed by 2.5 mg increments when clinically appropriate.

Recorded protocol library

Amounts recorded for Tirzepatide

These amount records are independent from vial strength, reconstitution volume and measuring device. A recorded source is not the same as study backing, and these values are not recommendations.

  • 01

    SURMOUNT-1 initiation step

    2.5 mg

    Sign in for schedule, duration and source context.

  • 02

    Lower SURMOUNT-1 target arm

    5 mg

    Sign in for schedule, duration and source context.

  • 03

    Conservative SURMOUNT-1 cap

    10 mg

    Sign in for schedule, duration and source context.

Technical reference

Identity, limitations and unknowns

Molecular profile

Class
Acylated dual GIP/GLP-1 receptor agonist
Amino acids
39
Approx. MW
4813.5 Da
Origin / design
Engineered from the native GIP sequence with GLP-1 receptor activity

Important limitations

  • The 2.5 mg initiation dose is not a maintenance dose.
  • Risk, contraindication, and interaction information must come from current regulated labeling.
  • A calculator preset is a recorded research convention, not a recommendation or evidence of clinical benefit.
  • Identity, purity, sterility, and stability can vary substantially outside regulated manufacturing.
  • Route, formulation, and population can make results from one study inapplicable to another use.

Curated sources

2 curated references

  1. Tirzepatide Once Weekly for the Treatment of ObesityNew England Journal of Medicine · 2022 · Human
  2. Tirzepatide for Obesity Treatment and Diabetes PreventionNew England Journal of Medicine · 2024 · Human

Related profiles